Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MiRA

Financiado

Miniaturised Respiratory Assist to treat acute lung failure patients using a bre...

Miniaturised Respiratory Assist to treat acute lung failure patients using a breakthrough hyperbaric technology Acute lung failure (ALF) is the third leading cause of death globally and is characterised by severe respiratory impairment. When non-invasive ventilation (NIV) fails, the treatment escalates to invasive mechanical ventilation (IM... ver más

31/08/2026

HBOX THERAPIES GMB...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

HBOX THERAPIES GMBH No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-08

HORIZON-EIC-2023-ACCELERATOROPEN-01: EIC Accelerator Open 2023 Scope:The EIC Accelerator Open has no predefined thematic priorities and is open to proposals in any...

I+D

Cerrada hace 1 año

0% 56% 100%

1 Participantes

HBOX THERAPIES GMBH

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

LIFT Liquid Foam Therapy LIFT for Acute Respiratory Distress Sy... 150K€ Cerrado

PDC2023-145905-I00 Ingeniería biomédica 289K€ Cerrado

Luncolive Saving Cardiac Arrest Patients with Hypothermic Lung Conserv... 4M€ Cerrado

CPP2021-008930 DESARROLLO DE UN EQUIPO DE MONITORIZACIÓN Y VENTILACIÓN MECÁ... 195K€ Cerrado

PID2019-106564RJ-I00 MEDICINA DE PRECISION BASADA EN EL PERFIL METABOLICO PARA PA... 182K€ Cerrado

RTC-2017-6193-1 SMARTVENT: Uso de algoritmos sobre señales fisiológicas para... 329K€ Cerrado

Duración del proyecto: 30 meses Fecha Inicio: 2024-02-08
Fecha Fin: 2026-08-31

Líder del proyecto

HBOX THERAPIES GMBH No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Descripción del proyecto Acute lung failure (ALF) is the third leading cause of death globally and is characterised by severe respiratory impairment. When non-invasive ventilation (NIV) fails, the treatment escalates to invasive mechanical ventilation (IMV) - the current standard of care for ALF. IMV is highly invasive, with a high risk of complications and an avg. in-hospital mortality rate of 35%, costing thousands of euros per patient. Hospitals have signalled an unmet need for safe and adequate alternatives to IMV in ALF. HBOX Therapies GmbH is bringing MiRA (Miniaturised Respiratory Assist) to market: a disruptive and innovative hyperoxygenation therapy that combines unrivalled blood oxygenation and CO2 removal to treat ALF patients, while they are awake. Such a breakthrough therapy has the potential to be the first treatment option for ALF patients who fail NIV. MiRA therapy has an outstanding cost-effectiveness and improved patient outcomes by avoiding or limiting the need for IMV and further respiratory deterioration in these patients. The growing incidence & prevalence of respiratory diseases causing ALF suggests that there are up to 6 million ALF patients who could benefit from MiRA every year, representing a market potential of €10.4 B/year. Behind MiRA, there is our extracorporeal hyperbaric blood oxygenation (HBOX) technology - 2 patents protect the technology and the approach. HBOX has been validated in animal trials (TRL 5) and we now need to: i) finalise the integrated system for improved safety & efficacy, ii) complete clinical studies, and iii) obtain MDR/CE certification for the MiRA medical device to commence commercialisation. We expect the results of the MiRA project to accelerate the market entry of HBOX and to serve as a platform technology for additional clinical applications in the future. The EIC support will be key for our company to establish itself as a leading company in the respiratory industry.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores